
GAU1646



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Serial No.

James K. Liao, et al.

RECEIVED

Filed:

09/273,445 March 19, 1999

For:

UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE 8 2001;

SYNTHASE BY HMG-COA REDUCTASE INHIBITORS

Examiner:

not yet assigned

TECH CENTER 1600/2900

Art Unit:

1646

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the 30th day of November, 2000.

Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- [X] Respone to Restriction Requirement
- [X] Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,

Attorney's Docket No.: R0547/7007

Date: November 30, 2000

x11/30/00

Edward R. Gates, Reg. No.: 31,616 WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue Boston, MA 02210-2211

(617)720-3500



ATTORNEY'S DOCKET NO.: R0547/7007(ERG/KA)

ATES PATENT AND TRADEMARK OFFICE IN THE

Applicant:

LIAO, James K.

Serial No.:

09/273,445

Filed:

March 19, 1999

For:

UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE

BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION

Examiner:

not yet assigned

Art Unit:

1646

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with firstclass postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 30th day of November, 2000.

Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement (paper 8) mailed from the United States Patent and Trademark Office on October 30, 2000, Applicants elect Group I, drawn to "methods of use," and elect species (g) "a method for increasing blood flow" Claims 167-204, 213-216 (and not Claims 205-206 as designated by the Examiner in the Restriction Requirement), for further prosecution on the merits.

REMARKS

In the event that the elected species (g) claims are found allowable, Applicant's respectfully request that the examiner rejoin the non-elected claims of species (a) - (f) and (h) for further prosecution in this application.

Respectfully Submitted,

d R. Gates, Reg. No.: 31,616

WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue Boston, MA 02210-2211

(617)720-3500

Attorney's Docket No.: R0547/7007

Date:

x11/30/00

497980.1